l-DOPA and its receptor GPR143: Implications for pathogenesis and therapy in Parkinson's disease

Yoshio Goshima, Daiki Masukawa, Yuka Kasahara, Tatsuo Hashimoto, Aderemi Caleb Aladeokin

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD.

Original languageEnglish
Article number1119
JournalFrontiers in Pharmacology
Volume10
DOIs
Publication statusPublished - 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'l-DOPA and its receptor GPR143: Implications for pathogenesis and therapy in Parkinson's disease'. Together they form a unique fingerprint.

Cite this